Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Gilead plans to develop HCXT-2001 both as a monotherapy and in combination with its own IBD hopeful, emvistegrast.